Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23580162 | 0.95 | PLAU (0.40) | PLAUBCHEHTTKMT2ASMN1; SMN2 | |
| SCHEMBL16000809 | 0.80 | PLAU (0.36) | PLAUHTTKMT2AALDH1A1GAA | |
| SCHEMBL18668140 | 0.77 | PLAU (0.37) | PLAUSMN1; SMN2ALDH1A1CNR2 | |
| SCHEMBL23580260 | 0.75 | THRB (0.32) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL27020188 | 0.74 | PLAU (0.39) | PLAUHTTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15992767 | 0.72 | GPR119 (0.41) | KMT2ASMN1; SMN2MAPT | |
| SCHEMBL23608527 | 0.71 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL14920534 | 0.71 | PLAU (0.44) | PLAUHTTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15265393 | 0.71 | PKM (0.32) | SMN1; SMN2GAA | |
| SCHEMBL14919923 | 0.70 | PLAU (0.36) | PLAUHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | PURDUE PHARMA L.P. | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249159-A1 | HETEROCYCLIC COMPOUNDS | HRH2, UGT1A3, UGT1A1 | PLAU 3771/4885BCHE 4137/4885HTT 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.